Abstract
Background. Community-acquired pneumonia (CAP) remains one of the most common infectious diseases, occupying an important place in the structure of mortality worldwide.Aim. To evaluate the effectiveness of antimicrobial therapy for community-acquired pneumonia in hospitalized patients in real clinical practice.Materials and methods. A retrospective, observational study was conducted, which included 236 patients hospitalized for community-acquired pneumonia at the Regional Clinical Hospital in Ryazan in 2019. Based on these case histories, an analysis of the effectiveness of the initial empiric antimicrobial therapy was performed.Results. The initial empiric antimicrobial therapy in 73% of cases included administration of ceftriaxone, in 45% of cases – levofloxacin, in 14% of cases – azithromycin. It was found that initial antimicrobial therapy was effective in 58% of patients who did not require replacement for the antibiotic. A need for a change in the treatment regimen was significantly associated with an increase in the length of hospitalization (p < 0.001), heart rate upon admission (p = 0.032), myelocyte count in the complete blood count (p < 0.001), and urea and blood creatinine levels (p = 0.004 and p = 0.044, respectively). The selected antimicrobial therapy regimen was significantly associated with the expected treatment effectiveness (p = 0.039). The choice of levofloxacin in monotherapy or in combination with ceftriaxone was accompanied by a decrease in the relative risk of replacing the antimicrobial, compared with other treatment regimens (odds ratio (OR) = 0.86 (95% confidence interval (CI): 0.55–1.34) and OR = 0.57 (95% CI: 0.37–0.87), respectively).Conclusion. Empiric antimicrobial therapy for community-acquired pneumonia in real clinical practice complies with current recommendations, however, at the same time, its ineffectiveness persists. Respiratory fluoroquinolones are most effective in treating pneumonia in hospitalized patients.
Highlights
Community-acquired pneumonia (CAP) remains one of the most common infectious diseases, occupying an important place in the structure of mortality worldwide
A retrospective, observational study was conducted, which included 236 patients hospitalized for community-acquired pneumonia at the Regional Clinical Hospital in Ryazan in 2019
It was found that initial antimicrobial therapy was effective in 58% of patients who did not require replacement for the antibiotic
Summary
Цель – оценить эффективность антибактериальной терапии внебольничной пневмонии у госпитализированных пациентов в условиях реальной клинической практики. Установлено, что стартовая антибактериальная терапия была эффективной у 58% пациентов, которым не потребовалась замена антибиотика. Выбранная схема стартовой антибактериальной терапии значимо ассоциирована с ожидаемой эффективностью лечения (p = 0,039). Эмпирическая антибактериальная терапия внебольничной пневмонии в целом соответствует действующим рекомендациям, однако при этом сохраняется крайне высокая частота ее неэффективности. Наибольшую эффективность в лечении пневмонии у госпитализированных пациентов имеют респираторные фторхинолоны. Авторы заявляют об отсутствии финансирования при проведении исследования. Для цитирования: Урясьев О.М., Шаханов А.В., Коршунова Л.В. Эффективность антибактериальной терапии внебольничной пневмонии в условиях реальной клинической практики.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
